GLP-1Microvascular HealthGlycoCheckReVascaMuscle and Metabolism

What the scale misses GLP-1 medicines, your circulation, and the half of your weight loss nobody measures

Here is the part that surprises people: on the evidence, GLP-1 drugs are good for your blood vessels — in a randomized trial they improved the endothelial glycocalyx more than insulin did, despite achieving a similar reduction in blood sugar.[1] The problem is not the medicine. The problem is that the only number most people watch is body weight, and roughly 28% of the weight that comes off is muscle-based tissue[6] — and nobody is measuring what happens to your smallest blood vessels while it does. This article is about the other half: what to protect, what to eat, and what to measure.

Robert Long
By Robert Long, Co-Founder, GlycoCalyx Research Institute
Published September 1, 2026 · 30-minute read · Part of the Genesis Health Sciences family
A weight-loss curve descending into a GlycoCheck scope view of a capillary bed, where some capillary loops are drawn as ghosts to show rarefaction
The line everyone watches is body weight. Inside the scope is the thing it never weighed: the capillary bed, with some vessels no longer carrying blood.

The short version

  • GLP-1 drugs help the microcirculation. In a 160-person randomized trial, 12 months of a GLP-1 receptor agonist reduced the perfused boundary region — a direct measure of glycocalyx thickness — more than insulin did, despite a similar HbA1c reduction. The vascular benefit is not just the glucose.[1,2]
  • They also actively recruit your muscle microcirculation, expanding perfused capillary surface area and increasing delivery of insulin, glucose and amino acids to muscle.[3]
  • But the weight that comes off is not all fat. Across 35 trials, the median share of weight loss attributable to muscle-based tissue was 28.3% (interquartile range 15.9–39.9%), and two thirds of studies exceeded the expected benchmark.[6] That is worth defending against — muscle is the body’s main glucose disposal site, and it decides what your body composition looks like if you regain weight later.
  • It is not, however, a microvascular injury. The capillaries lost with muscle are the ones that were inside it; density in the muscle you keep is not reduced, and neither is the glycocalyx lining it. Our Chief Science Officer was firm on that point, and the article says so where most coverage does not.[12]
  • Intake falls with appetite. Across 480,825 adults, more than 60% of GLP-1 users consumed below requirements for calcium and iron, vitamin D intake averaged about 20% of recommendations, and thiamine and B12 deficits grew over time.[10]
  • The fix is not to stop the medicine. It is protein at ≥1.2 g/kg/day, resistance training at least twice a week, a real micronutrient floor[9] — and measuring the microcirculation instead of assuming it.
  • Nothing here is a reason to avoid GLP-1 therapy. Weight loss itself improves microvascular endothelial function.[12,13] This is about keeping what you should not lose while you lose what you should.

Start with the evidence

What GLP-1 medicines actually do to your blood vessels

In one sentence: semaglutide, liraglutide, dulaglutide and tirzepatide improve the health of the small vessels — measurably, in randomized trials, using the same glycocalyx measurement we use in clinic — so the honest starting point is that the drug is helping the circulation, not harming it.[1,2,3]

If you have arrived here because you searched something like “does GLP-1 affect blood flow” or “GLP-1 and circulation problems”, the answer is probably not what you expected. Let us deal with it properly before we get to the part that does deserve your attention.

The glycocalyx result nobody talks about

The endothelial glycocalyx is the thin, gel-like coating of sugars and proteins that lines the inside of every blood vessel you own. It keeps vessels sealed, keeps blood cells from scraping the wall, senses flow so the vessel can release nitric oxide, and holds your own antioxidant enzymes against the endothelium.[21] When it thins, capillaries leak, clot and stop carrying blood. It is one of the earliest measurable changes in vascular disease, and a thin glycocalyx predicted a six-fold higher risk of heart attack, stroke or death over six years in people with no known heart disease.[23] If you want the full primer, start with what the glycocalyx is.

In 2020 a group in Athens randomized 160 people with type 2 diabetes to insulin, liraglutide (a GLP-1 receptor agonist), empagliflozin (an SGLT-2 inhibitor), or the GLP-1 and SGLT-2 combination, all on top of metformin. They measured the perfused boundary region — the same sublingual marker of glycocalyx thickness a GlycoCheck™ test reports — at baseline, four months and twelve months.[1]

Everyone improved. But the GLP-1 arm, the SGLT-2 arm and the combination all improved the perfused boundary region more than insulin did — and here is the important part — despite achieving a similar HbA1c reduction. That control is what makes the finding interesting. It means the glycocalyx benefit is not simply the downstream effect of lower blood sugar; something about these drug classes acts on the vessel lining itself.

Why the control matters

High blood glucose degrades the glycocalyx directly and quickly — a six-hour hyperglycaemic clamp is enough to strip it measurably in healthy volunteers.[22] So any glucose-lowering drug should improve the layer a little. The 2020 trial holds glucose control constant between arms and still finds a GLP-1 advantage, which is a much stronger claim than “it lowers sugar, so it must help.”

A second trial from the same group in 2024 found that a dulaglutide plus dapagliflozin combination improved the glycocalyx, arterial function and myocardial function together in people with type 2 diabetes and albuminuria, compared with a DPP-4 inhibitor.[2] The direction of travel is consistent.

They also recruit the capillaries in your muscle

A 2026 review in Comprehensive Physiology framed skeletal muscle exactly the way we would — as an integrated unit of vasculature and muscle cells — and reached a striking conclusion. GLP-1 and GLP-1 receptor agonists recruit microvasculature in muscle, expanding capillary surface area and increasing the delivery of insulin, glucose and amino acids to the tissue.[3] More perfused capillary surface means more interstitial insulin, which potentiates glucose uptake and glycogen synthesis. It can also enhance muscle protein synthesis when amino acids are available in the blood — a point we will come back to, because it is the hinge of this whole article.

And the hard outcomes agree

Two large trials matter here. In SELECT, semaglutide reduced major cardiovascular events in 17,604 people with overweight or obesity and established cardiovascular disease but without diabetes.[4] In FLOW, semaglutide reduced kidney-disease progression and cardiovascular and kidney death in people with type 2 diabetes and chronic kidney disease.[5] The kidney result is worth pausing on: the kidney is essentially a specialised microvascular organ, and its filtration barrier is glycocalyx-dependent. A drug that protects kidney function is a drug doing something right for small vessels.

The clue in that result: this is a pleiotropic effect

It is worth sitting with the Athens finding a moment longer, because it says something bigger than “GLP-1 drugs are good for you.” If the glycocalyx improved more than the glucose control alone can account for, then the layer was responding to something else the drug does — anti-inflammatory signalling at the endothelium, reduced oxidative stress, altered shear sensing, or some combination we have not fully mapped. In pharmacology that is called a pleiotropic effect: a benefit outside the drug’s headline mechanism.

Our Chief Science Officer’s reading of it

Dr Hans Vink, who reviewed this article, regards this as the most informative result in the set: the glycocalyx improved by more than equivalent glucose control accounts for, which indicates the layer responds to targeted signals rather than only to metabolic tidiness — the premise behind addressing it deliberately.

That is a genuinely encouraging finding for anyone taking these medicines, and it points somewhere specific. If a drug developed for glucose and appetite can move the glycocalyx as a side effect, the obvious next question is what happens when you target the layer on purpose — which is the work the Institute exists to do, and the reason the last step of this article is measurement rather than assumption.

On the evidence available, GLP-1 therapy is one of the better things you can do for your microcirculation. The question this article asks is not whether to take it. It is what else you need to be doing at the same time.

The blind spot

What muscle loss does — and doesn’t do — to your circulation

In one sentence: between a quarter and a third of the weight you lose comes off muscle[6], and while that is worth defending, it is not the same thing as damaging your microvascular network — a distinction our Chief Science Officer was firm about, and one most coverage of this topic gets wrong.

The number

In 2026 the Annals of Internal Medicine published a systematic review of 35 randomized trials reporting body composition on liraglutide, semaglutide, tirzepatide or dulaglutide. Within the incretin groups, the median proportion of total weight loss attributable to reductions in muscle-based indices was 28.3%, with an interquartile range of 15.9% to 39.9%. Two thirds of studies exceeded the prespecified benchmark of about 25%.[6]

28.3%median share of weight lost that came off muscle-based tissue
16–40%interquartile range across 35 trials — the spread is enormous
−5.4 kgpooled absolute lean-mass change on semaglutide in a 2026 meta-analysis

A separate 2026 meta-analysis of seven randomized trials (821 patients) found absolute lean mass fell by 1.74 kg on GLP-1 receptor agonists overall, and by 5.44 kg on semaglutide specifically.[7] Its authors also make the fair counterpoint, and we should make it too: lean mass as a proportion of total body weight actually improved by 1.81%. You end up a leaner person. Their conclusion is not “avoid these drugs” but “accompany them with nutritional and exercise interventions”.[7,8]

The correction: this is not a microvascular injury

It is tempting — and we very nearly wrote it this way — to draw a straight line from “you lost muscle” to “so you lost capillaries, and your microcirculation is worse.” Dr Hans Vink, who has spent two decades measuring exactly this, pushed back on that reasoning, and he is right to.

Corrected in review by Dr Hans Vink, PhD

The capillaries that disappear with lost muscle are the ones that were inside that muscle — the tissue and its blood supply go together. That is not the same thing as damage to the microvascular network you still have, and Dr Vink asked us to draw the distinction plainly.

The distinction matters. Capillary density — the number of vessels serving a given amount of tissue, which is what actually governs delivery — is not automatically reduced by having less tissue. Nor is the glycocalyx lining the vessels that remain. Losing weight is not a microvascular insult; on the measured evidence it is the opposite, and short-term weight loss has been shown to reverse obesity-induced microvascular endothelial dysfunction.[12,13]

So why care about the muscle at all?

Because of what muscle does, not because of what its loss does to your vessels. Skeletal muscle is the largest insulin-sensitive tissue in the body and the main disposal site for glucose; less of it means a smaller metabolic sink, lower resting energy expenditure, and less functional reserve as you age. And it sets up the problem in the next paragraph.

The part that really does deserve attention: what comes back

Weight regain after stopping is common, and the tissue that returns is not necessarily the tissue that left. Regaining fat without regaining muscle leaves you with a worse body composition than you started with — the same weight, less of it metabolically useful. That is the durable risk in this whole picture, and it is decided by what you do during the losing phase: protein intake, resistance training, and the raw material to rebuild with.

There is a second-order effect worth understanding here. Recall that GLP-1 drugs increase muscle protein synthesis when plasma amino acids are available.[3] The drug opens the delivery route — it recruits the very capillaries that carry amino acids into muscle. If you are not eating enough protein, it delivers very efficiently to a muscle that has nothing to build with. The medicine and the meal have to arrive together.

Muscle is still, for the record, a densely vascularised tissue: capillary density there governs how much insulin, oxygen and amino acid reaches the cells, and it falls with both ageing and type 2 diabetes.[15] The glycocalyx lining those capillaries thins with age too.[25] In older adults, sarcopenia travels together with impaired microcirculation, inflammation and oxidative stress.[16] Those are reasons to measure the microcirculation directly rather than to infer it from a body-composition scan — which is exactly what the rest of this article is about.

The second gap

The nutrient gap nobody orders labs for

In one sentence: these drugs work by making you want to eat less, and eating less means taking in less of everything — including the protein your muscle needs and the micronutrients your endothelium runs on.[10,9]

A 2026 narrative review in Clinical Obesity pulled together six studies covering 480,825 adults on GLP-1 receptor agonist therapy. The findings are not subtle:[10]

  • More than 60% of users consumed below estimated requirements for calcium and iron.
  • Vitamin D intake averaged about 20% of recommendations, and vitamin D deficiency was the most common abnormality found.
  • Thiamine and B12 deficits increased over time — these are cumulative, not immediate.
  • Protein and calcium insufficiency contributed to lean-mass loss directly.

The mechanisms are exactly what you would guess: appetite suppression, delayed gastric emptying, and altered absorption, on top of the fact that baseline micronutrient inadequacy is already common in people carrying excess weight.[10] The review is honest that its evidence is mostly observational and cannot prove causation. But the direction is clear enough to act on, and a 2026 paper in Advances in Therapy makes the same case specifically for protein and the risk of secondary sarcopenia.[11]

Why the endothelium cares

The vessel lining is not a passive pipe. Rebuilding a glycocalyx means synthesising glycosaminoglycans and proteoglycans; defending it means keeping superoxide dismutase and catalase active at the endothelial surface; producing nitric oxide requires substrate and cofactors. A diet that has quietly dropped to 1,100 calories of whatever is easiest to keep down is not a good environment for any of that. Nutrition and lifestyle demonstrably move the glycocalyx in both directions.[27]

The panel worth asking for

A 2026 review in Clinical Nutrition ESPEN proposes a practical framework for exactly this situation — a dietitian-led structure of energy floors, protein targets and a laboratory panel.[9] Its suggested panel is a reasonable thing to raise with your prescriber:

What to check Why it matters on a GLP-1
Vitamin D The most commonly deficient nutrient found in GLP-1 users; intake averages about a fifth of recommendations.[10]
Vitamin B12 Deficits accumulate over months rather than appearing early.[10]
Iron studies (incl. ferritin) Over 60% consume below requirement; ferritin runs lower than in comparator drug classes.[10]
Folate Part of the standard panel where intake has fallen sharply.[9]
Zinc Same rationale; commonly under-consumed on a much smaller food volume.[9]
Thiamine (higher-risk patients) Deficits increase with time on therapy, especially with vomiting or very low intake.[10,9]
Body composition (DXA or BIA) The only way to see whether the weight coming off is fat or muscle.[9]
Ask, do not self-prescribe

This is a list to take to the clinician who prescribed your medication, not a shopping list. Some of these — iron in particular — are actively harmful to supplement without a measured deficiency.

Where our own formula sits

Where the problem is a diet that has simply got smaller rather than one specific deficiency, that is the gap ReCelyx™ was built for — the Institute’s daily formulation, previously sold as ReNeu and renamed in 2026. It is worth being concrete rather than vague about it, because the overlap with the list above is the whole point: its 37-ingredient panel includes vitamin D, methylcobalamin B12, methylfolate, chelated zinc, thiamin and chelated calcium — six of the seven nutrients the GLP-1 literature flags as commonly short.[10,9]

What it is

A broad daily base in absorbable forms — methylated folate and B12, minerals prepared as chelates. Four capsules a day. See the full Supplement Facts →

What it is not

Not a treatment for a diagnosed deficiency, and not a substitute for testing. It also contains 2 mg of iron — a small amount, but tell your clinician if you are already supplementing iron.

ReCelyx™ is in production and currently out of stock; the product page takes waitlist sign-ups for the first run.

Interactive

Work out the other half of your weight loss

The numbers above are population medians. They are not your numbers — only a body-composition scan and a microvascular measurement can give you those. But they are a much better starting point than assuming all of it was fat, and they make the protein arithmetic concrete. Put your figures in.

GlycoCalyx Research Institute

The other half of your weight loss

Estimates the muscle-based share of what you have lost, and the daily protein intake the evidence suggests you need to hold on to the rest.
lb
lb
per week

What that most likely means

Split of the weight you have already lost, using the median and interquartile range from 35 randomized trials.[6]

Fat and other tissue Muscle-based (median) Plausible range

Likely muscle-based loss

8.5 lb Plausible range 4.8–12 lb, from the spread across trials.

Protein to aim for

115–150 g/day About 30–40 g at each of four meals.

Resistance training

1 / week One short of target

How this is calculated. Muscle-based share: median 28.3% of total weight lost, interquartile range 15.9–39.9%, from a systematic review of 35 randomized incretin trials.[6] Protein: 1.2–1.6 g per kg of current body weight per day, with roughly 0.3–0.4 g/kg at each meal, as proposed for adults on GLP-1 therapy without chronic kidney disease.[9] Resistance-training target: at least two sessions a week.

This is an educational estimate from population averages, not a measurement of you, and not medical advice. If you have kidney disease, are pregnant, or are managing another condition, your protein target may be different — ask the clinician who prescribed your medication before changing anything.

Two things usually stand out when people run this. The first is how much protein the target actually is — it is often more food than they are currently managing in a day, at a time when appetite is deliberately suppressed. The second is the width of the range. That 16–40% spread is not measurement noise; it is the difference between people who protected their muscle and people who did not.

Checklist

Six things to protect while the weight comes off

In one sentence: keep the protein up, keep lifting, keep the micronutrient floor under a much smaller diet, keep moving, feed the vessel lining, and measure the result instead of guessing at it.

Tick these off as you put them in place. The list stays on this device, so you can come back to it.

0 of 6in place. Nothing on this list requires stopping or changing your medication.

Saved in this browser only — nothing is sent anywhere, and no account is needed. Educational guidance, not medical advice; decisions about your medication belong with your prescriber.

The one that people skip

In practice it is number one that fails. Everything else on this list is a decision you make once — book the labs, join the gym, start the supplement. Protein is a decision you make three or four times a day, against a drug that is specifically designed to make you not want to. If you take one thing from this article, make it that: on a GLP-1, protein is not a nutrient you fit around your appetite. It is the thing you eat first.

The complete system

Four roles, in the GLP-1 context

In one sentence: the checklist above has four distinct jobs inside it — keep the delivery network healthy, keep the micronutrients coming in, supply the building blocks to rebuild with, and measure whether any of it worked — and the Institute built one thing for each.

We did not design this system for GLP-1 users. It came out of twenty years of asking why nutrition so often fails to show up in a measurement. But the four gaps a GLP-1 opens map onto it almost exactly, which is why it is worth setting out plainly.

ReVasca, ReCelyx and ReMyolyx bottles together
The road, the nutrients, the building blocks — and a way to observe the outcome.
The gap a GLP-1 opens The role What it is
Delivery The road ReVasca® supports the microcirculation and the endothelial glycocalyx — the network everything else has to travel through.*
Intake falls with appetite The nutrients ReCelyx™ supplies micronutrients in absorbable forms, covering six of the seven nutrients the GLP-1 literature flags as commonly short.*[10]
Protein is hard to hit The building blocks ReMyolyx™ provides 24 free-form amino acids — a practical complement to dietary protein where food volume is the limiting factor, never a replacement for it.*
Nobody is measuring The observation GlycoCheck™ measures microvascular health non-invasively, so the result can be observed rather than assumed.

Why free-form amino acids, specifically

Every gram of protein you eat has to be broken down into individual amino acids before your body can use any of it. That is ordinarily no obstacle at all — but it does mean the useful dose is capped by how much food you can physically get down. On a medicine whose entire purpose is to reduce that, the arithmetic changes. Free-form amino acids start where digestion ends.

Say this precisely, because the distinction matters

ReMyolyx™ is a dietary supplement intended to complement dietary protein, not to replace it. It is not intended to alter the action of any medication, and nothing here suggests it does. Phenylketonurics: it contains L-phenylalanine. Eat the protein; use amino acids where the food volume genuinely will not fit.

Both ReCelyx™ and ReMyolyx™ are in production and currently out of stock — their pages take waitlist sign-ups for the first run. Explore ReCelyx™ · Explore ReMyolyx™

Close the loop

What to measure — and what the scale can’t tell you

In one sentence: weight, HbA1c and a lipid panel are all downstream proxies; the microcirculation is the tissue where the damage and the recovery actually happen — it predicts cognitive decline and small-vessel disease downstream[36] — and it can be filmed in about five minutes without a needle.[30,23]

Consider what a typical GLP-1 review appointment measures. Body weight. Perhaps waist circumference. HbA1c if you have diabetes. A lipid panel once a year. Blood pressure. Every one of those is a number about the whole body or about the blood. None of them is a number about your vessels.

A GlycoCheck™ assessment films the capillaries under your tongue with a small camera and reports two things that matter here:

1

Perfused boundary region (PBR)

How far red cells push into the glycocalyx. A larger PBR means a thinner, more permeable layer, and deeper red-cell penetration tracks with genuinely impaired microvascular perfusion.[24] In 600 people with no known heart disease, a higher PBR predicted a six-fold higher risk of heart attack, stroke or death over six years.[23] It is the marker that improved on GLP-1 therapy in the Athens trial.[1]

2

Capillary density and MVHS

How many capillaries are actually carrying blood, rolled up with PBR into a single MicroVascular Health Score. This is the number that speaks to the muscle question — it is the closest thing you have to watching whether your capillary bed is holding up while your body composition changes.

The practical value is not the single reading. It is the comparison. The GlycoCheck system is reproducible enough under controlled conditions to compare a person against their own earlier result[30], which is what turns a supplement or a training programme from a hope into a measured outcome. Our companion article sets out the full method: Measure. Restore. Verify.

A sensible schedule if you are starting a GLP-1

Baseline before you start, or as early in the course as you can. Body composition (DXA or BIA) at the same time.[9] Retest the microcirculation at around six months, once a meaningful amount of weight has moved. Then annually. Keep the conditions the same each time — time of day, no food, drink or exercise immediately beforehand.

You can find a clinic with a GlycoCheck device here, and clinicians can read about bringing the device into practice.

Where the evidence is still thin

We should be straight about the limits of our own field. Human trials of glycocalyx-targeted nutrition are few, and they are not uniformly positive. Four-month randomized trials in psoriasis and after COVID-19 infection improved glycocalyx measures and vascular function[31,32], as did a dietary intervention trial in South-Asian Surinamese adults with type 2 diabetes.[33] Two small pilots did not meet their primary endpoints — and both are worth reading properly rather than filing as failures.

  • A 22-person, 8-week pilot in Veterans with type 2 diabetes found no improvement in glycocalyx integrity or vascular function against placebo — although in the same paper, the mouse arm showed the supplement restored glycocalyx length and improved flow-mediated dilation.[34]
  • A 23-person, 12-week trial in older adults found no effect on overall glycocalyx thickness or raw flow-mediated dilation — but did significantly improve flow-mediated dilation normalised to the shear stimulus, and did increase capillary glycocalyx thickness more than placebo in the participants who were not taking antihypertensive medication.[35]

Those are small studies and secondary findings, so they generate hypotheses rather than settle anything. But the pattern they suggest is the one clinicians see: the people with the most room to improve are the ones who improve most, and a group average can hide that completely. No trial to date has studied glycocalyx nutrition specifically in people taking a GLP-1.

That is not an argument against doing it. It is the argument for the last step: measure, so you find out what happened to you rather than to a trial average.

Glycocalyx support · Subscribe & save 10% ReVasca capsules bottle and ReVasca grape drink mix jar

Feed the vessel lining

ReVasca® Endothelial Glycocalyx Support

4.5 / 5 · 55 verified reviews

The Institute’s flagship formula, built for exactly this job: supplying the layer while the rest of the diet gets smaller. One month per bottle — 120 capsules (4 a day) or 30 servings of grape drink mix.

  • Glycocalyx building blocks: hyaluronic acid, fucoidan, aloe polysaccharides
  • Nitric-oxide support: L-citrulline and ViNitrox® polyphenols
  • Antioxidant enzymes: superoxide dismutase and catalase
Added to your cart — view cart & check out →
Contains soybeans.·Backed by our money-back guarantee·3-packs & all options·Practitioner? Wholesale & clinic pricing

Nuance

Three situations that need extra care

1. If you have diabetic retinopathy

This is the one genuine microvascular caution, and it deserves stating plainly. In SUSTAIN-6, semaglutide was associated with a higher rate of diabetic retinopathy complications than placebo[17], and a 2025 real-world cohort found early worsening of diabetic retinopathy in people with type 2 diabetes started on tirzepatide.[18] The leading explanation is not that the drug damages the retina but that a rapid fall in blood glucose after a long period of poor control can transiently destabilise already-fragile retinal vessels — a phenomenon known long before these drugs existed.

The response is monitoring, not avoidance. A 2026 review sets out risk-stratified ophthalmic monitoring for exactly this group.[19] There has also been a reported association between semaglutide and non-arteritic anterior ischaemic optic neuropathy, which remains under investigation and is rare.[20] If you have any retinopathy, tell your prescriber before you start and get your eyes checked on the schedule they set.

2. If you have chronic kidney disease

Two things are true at once here. The kidney evidence is genuinely good — semaglutide reduced kidney-disease progression and cardiovascular and kidney death in FLOW.[5] But the protein guidance in this article explicitly excludes people with chronic kidney disease[9], for whom higher protein intake is not automatically safe. If that is you, the muscle-protection conversation has to happen with your kidney team, not with a calculator.

3. When you come off

Weight regain after stopping is well documented, and as the muscle section set out, the tissue that comes back is not necessarily the tissue that left. This is the single most consequential moment in the whole cycle and the one people plan for least.

The practical implication is that the regain phase is when protein intake and resistance training matter most, not least — you are trying to steer returning mass toward muscle rather than fat, and appetite is no longer suppressed to help you. It is also the phase where having the building blocks on hand stops being a nicety: free-form amino acids and a micronutrient floor are cheap insurance against rebuilding the wrong tissue. Do the work during the losing phase; keep doing it through the regain.

What this article is not saying

It is not saying GLP-1 drugs damage your circulation — the measured evidence says the opposite.[1,2,4,5] It is not telling you to stop or reduce a prescribed medication. It is saying that a treatment this effective deserves a measurement plan that goes beyond a bathroom scale.

Answers

Frequently asked questions

Do GLP-1 drugs affect blood flow and circulation?

Yes, and mostly for the better. In a randomized trial of 160 people with type 2 diabetes, twelve months of a GLP-1 receptor agonist improved the perfused boundary region — a direct marker of endothelial glycocalyx thickness — more than insulin did, despite a similar HbA1c reduction. GLP-1 receptor agonists also recruit the microvasculature within skeletal muscle, expanding perfused capillary surface area and increasing delivery of insulin, glucose and amino acids. The circulation concern with these drugs is not a direct vascular effect; it is the muscle and nutrient loss that accompanies rapid weight loss.

How much of the weight I lose on a GLP-1 is muscle?

Across 35 randomized trials, the median share of total weight loss attributable to muscle-based tissue was 28.3%, with an interquartile range of 15.9% to 39.9%. Two thirds of studies exceeded the expected benchmark of about 25%. A separate meta-analysis found absolute lean mass fell by about 1.74 kg on GLP-1 receptor agonists overall and about 5.44 kg on semaglutide specifically — though lean mass as a proportion of total body weight improved. Nearly half of non-drug weight-loss interventions also exceeded the benchmark, so this is largely a property of losing weight in an energy deficit rather than a specific drug toxicity.

How much protein should I eat on a GLP-1?

Published guidance for adults on GLP-1 therapy without chronic kidney disease is at least 1.2 g per kilogram of body weight per day, up to 1.6 g/kg in appropriate adults, with meal-wise targets of about 0.3 to 0.4 g/kg and roughly 2.5 to 3 g of leucine per meal. For a 95 kg adult that is roughly 115 to 150 g a day, spread across four meals. If you have kidney disease, pregnancy or another condition, this does not apply to you — ask your prescriber.

Should I take a multivitamin while on semaglutide or tirzepatide?

Discuss it with your prescriber, and ideally test rather than guess. Across 480,825 adults, more than 60% of GLP-1 users consumed below requirements for calcium and iron, vitamin D intake averaged about 20% of recommendations, and thiamine and B12 deficits increased over time. Vitamin D deficiency was the single most common abnormality. A broad micronutrient base makes sense when total food volume has fallen sharply, but iron in particular should only be supplemented against a measured deficiency.

Can a GLP-1 cause cold hands and feet or poor circulation symptoms?

There is no good evidence that GLP-1 receptor agonists directly impair peripheral blood flow — the measured vascular effects run the other way. Symptoms like feeling cold are more plausibly explained by a large energy deficit, reduced food and fluid intake, lower body mass and, in some people, iron deficiency or dehydration, all of which are common on these drugs. Persistent cold, numbness or colour change in the hands and feet should be assessed by a clinician rather than attributed to the medication.

Will resistance training actually protect my muscle on a GLP-1?

Progressive resistance training combined with adequate protein is the intervention every current review converges on for preserving lean mass during incretin-induced weight loss. It has a vascular dividend too: physical activity remodels the vasculature inside skeletal muscle, so training grows capillary supply rather than only muscle fibres. Two sessions a week is the usual minimum target.

Does ReVasca interact with semaglutide or tirzepatide?

ReVasca is a dietary supplement, not a drug, and it is not known to interact with GLP-1 receptor agonists. That said, anyone taking prescription medication should tell their prescriber about every supplement they take, and that is doubly true when a medication is being titrated. If you have a history of thyroid cancer, pancreatitis or gallbladder disease, or you are pregnant or breastfeeding, speak to your clinician first.

Can I measure my glycocalyx while I am on a GLP-1?

Yes, and it is arguably the best time to. A GlycoCheck test is non-invasive, takes about five minutes, and is reproducible enough under controlled conditions to compare against your own earlier result. Baseline before or early in your course, retest at around six months once a meaningful amount of weight has moved, then annually. Keep the conditions consistent between tests.

Does losing muscle on a GLP-1 damage my capillary network?

No — and this is a common misreading. The capillaries lost along with muscle tissue are the ones that were inside that tissue; capillary density in the muscle you keep is not thereby reduced, and neither is the glycocalyx lining those vessels. Losing excess weight is, on the measured evidence, good for the microcirculation: short-term weight loss has been shown to reverse obesity-induced microvascular endothelial dysfunction. Muscle loss is worth defending against for metabolic and functional reasons — muscle is the body's main glucose disposal site — and because of what comes back if you regain weight later. It is not a microvascular injury.

What should I take alongside a GLP-1?

Nothing is required, and nothing replaces the food. The three gaps a GLP-1 opens are protein (hard to hit on a suppressed appetite), micronutrients (intake falls across the board — vitamin D, B12, iron, folate, zinc, thiamine and calcium are the ones the literature flags) and measurement. Address protein with food first and free-form amino acids only where food volume is genuinely the limiting factor; address micronutrients by testing and treating what is actually low, with a broad daily base underneath; and get a microvascular baseline before the weight moves. Tell your prescriber about every supplement you take.

Is the muscle loss a reason not to take a GLP-1?

No. The cardiovascular and kidney outcome evidence for semaglutide is strong, weight loss itself improves microvascular endothelial function, and the muscle loss is largely addressable with protein and resistance training. The reason to know about it is so you can protect against it while the drug does its job — not so you can talk yourself out of an effective treatment.

What about the retinopathy warning?

In SUSTAIN-6, semaglutide was associated with more diabetic retinopathy complications than placebo, and a 2025 real-world cohort found early worsening of retinopathy after starting tirzepatide. The leading explanation is that a rapid fall in long-standing high blood glucose can transiently destabilise fragile retinal vessels — a phenomenon known well before these drugs existed. The response is risk-stratified eye monitoring rather than avoiding treatment. Tell your prescriber if you have any degree of retinopathy before you start.

In summary

The bottom line

GLP-1 medicines are, on the measured evidence, good for the small blood vessels — they improve the glycocalyx beyond what their glucose lowering alone explains[1], they recruit the capillary bed inside muscle[3], and they reduce hard cardiovascular and kidney outcomes.[4,5] If you are taking one, that is the headline, and it is a good one.

What they do not do is decide which tissue you lose, or what you manage to eat while losing it. About 28% of the weight coming off is muscle-based[6] — not a microvascular injury, as our Chief Science Officer is careful to say, but a real cost to your metabolic reserve and to what you rebuild with later — and a suppressed appetite quietly takes protein and micronutrients down with it.[10] None of that shows up on a scale, an HbA1c or a lipid panel.

So do both halves. Take the medicine your clinician prescribed. Then eat the protein, lift twice a week, put a floor under a smaller diet, supply the building blocks, feed the vessel lining, and measure the microcirculation instead of assuming it survived the process. That last step is the only one that tells you whether the rest of it worked.

Sources

References

Every reference below was verified against the PubMed record on September 1, 2026. Where we hold the abstract in our own research library, a second link is given.

  1. Ikonomidis I, Pavlidis G, Thymis J, et al. Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment (randomized, n=160). Journal of the American Heart Association. 2020;9(9):e015716. PubMed
  2. Korakas E, Thymis J, Oikonomou E, et al. Dulaglutide and dapagliflozin combination concurrently improves the endothelial glycocalyx and vascular and myocardial function in patients with T2DM and albuminuria vs. DPP-4i. Journal of Clinical Medicine. 2024;13(24):7497. PubMed
  3. Katsanos CS, Liu Z, Atherton PJ. Glucagon-like peptide-1 receptor agonism and muscle health: vascular and myocellular effects on glucose and protein metabolism. Comprehensive Physiology. 2026;16(2):e70126. PubMed
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT, n=17,604). New England Journal of Medicine. 2023;389(24):2221–2232. PubMed
  5. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW, n=3,533). New England Journal of Medicine. 2024;391(2):109–121. PubMed
  6. Batsis JA, Gavras A, Gross DC, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review (35 studies). Annals of Internal Medicine. 2026;179(7):996–1013. PubMed
  7. Laverde LP, Muñoz-Velandia OM, Alfonso D, Gómez Medina AM. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomised controlled trials (7 studies, n=821). International Journal of Obesity. 2026;50(8):1638–1646. PubMed
  8. Eisa N, Barood O, et al. Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. 2026;28(6):4818–4827. PubMed
  9. Arslan S. Medical nutrition in the GLP-1 era: protein strategies, micronutrient monitoring, and lean mass preservation. Clinical Nutrition ESPEN. 2026;73:103305. PubMed
  10. Urbina J, Salinas-Ruiz LE, Valenciano C, Clapp B. Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review (6 studies, n=480,825). Clinical Obesity. 2026;16(1):e70070. PubMed
  11. Prokopidis K, Cacciatore S, Anton SD, Batsis JA, et al. Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia. Advances in Therapy. 2026. PubMed
  12. Csipo T, Fulop GA, Lipecz A, et al. Short-term weight loss reverses obesity-induced microvascular endothelial dysfunction. GeroScience. 2018;40(3):337–346. PubMed
  13. Joris PJ, Plat J, Kusters YH, et al. Diet-induced weight loss improves not only cardiometabolic risk markers but also markers of vascular function: a randomized controlled trial in abdominally obese men. American Journal of Clinical Nutrition. 2017;105(1):23–31. PubMed
  14. Laughlin MH. Physical activity-induced remodeling of vasculature in skeletal muscle: role in treatment of type 2 diabetes. Journal of Applied Physiology. 2016;120(1):1–16. PubMed
  15. Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes. · In our library
  16. Lopes KG, Farinatti P, Bottino DA, et al. Sarcopenia in the elderly versus microcirculation, inflammation status, and oxidative stress: a cross-sectional study. Clinical Hemorheology and Microcirculation. 2022;80(2):185–195. PubMed
  17. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834–1844. PubMed
  18. Buckley AJ, Tan GD, Gruszka-Goh M, Scanlon PH. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study. Diabetologia. 2025;68(9):2069–2076. PubMed
  19. Song SJ, Kim E. Glucagon-like peptide-1 receptor agonists and ocular outcomes: metabolic transition, retinal vulnerability, and risk-stratified monitoring. Journal of Obesity & Metabolic Syndrome. 2026;35(2):164–175. PubMed
  20. Amini A, Hamann S, Larsen M. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association. Acta Ophthalmologica. 2025;103(6):615–621. PubMed
  21. Reitsma S, Slaaf DW, Vink H, van Zandvoort MAMJ, oude Egbrink MGA. The endothelial glycocalyx: composition, functions, and visualization. Pflügers Archiv. 2007;454(3):345–359. PubMed
  22. Nieuwdorp M, van Haeften TW, Gouverneur MCLG, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006;55(2):480–486. PubMed
  23. Ikonomidis I, Thymis J, Simitsis P, et al. Impaired endothelial glycocalyx predicts adverse outcome in subjects without overt cardiovascular disease: a 6-year follow-up study. Journal of Cardiovascular Translational Research. 2022;15(4):890–902. PubMed · In our library
  24. Lee DH, Dane MJC, van den Berg BM, et al. Deeper penetration of erythrocytes into the endothelial glycocalyx is associated with impaired microvascular perfusion (NEO study, n=915). PLoS ONE. 2014;9(5):e96477. PubMed · In our library
  25. Machin DR, Bloom SI, Campbell RA, et al. Advanced age results in a diminished endothelial glycocalyx. American Journal of Physiology – Heart and Circulatory Physiology. 2018;315(3):H531–H539. PubMed · In our library
  26. Potter DR, Jiang J, Damiano ER. The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro. Circulation Research. 2009;104(11):1318–1325. PubMed
  27. Franceković P, Gliemann L. Endothelial glycocalyx preservation — impact of nutrition and lifestyle. Nutrients. 2023;15(11):2573. PubMed
  28. Fuchs A, Neumann T, Drinhaus H, et al. Effects of a single aerobic exercise on perfused boundary region and microvascular perfusion: a field study. Journal of Clinical Monitoring and Computing. 2022;36(2):371–377. PubMed · In our library
  29. Schmitz B, Niehues H, Lenders M, et al. Effects of high-intensity interval training on microvascular glycocalyx and associated microRNAs. American Journal of Physiology – Heart and Circulatory Physiology. 2019;316(6):H1538–H1551. PubMed · In our library
  30. Eickhoff MK, Winther SA, Hansen TW, et al. Assessment of the sublingual microcirculation with the GlycoCheck system: reproducibility and examination conditions. PLoS ONE. 2020;15(12):e0243737. PubMed · In our library
  31. Ikonomidis I, Katsanaki E, Thymis J, et al. The effect of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx integrity and vascular function in patients with psoriasis (RCT, n=50). Nutrients. 2024;16(15):2572. PubMed
  32. Pavlidis G, Kountouri A, Katogiannis K, et al. Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection (RCT, n=57). European Journal of Clinical Investigation. 2025;55(7):e70058. PubMed
  33. van der Velden AIM, IJpelaar DHT, Chandie Shaw PK, et al. Role of dietary interventions on microvascular health in South-Asian Surinamese people with type 2 diabetes in the Netherlands: a randomized controlled trial. Nutrition & Diabetes. 2024;14:17. PubMed · In our library
  34. Smith JA, Ramirez-Perez FI, Burr K, et al. Impact of dietary supplementation of glycocalyx precursors on vascular function in type 2 diabetes (db/db mice + pilot RCT, n=22). Journal of Applied Physiology. 2024;137(6):1592–1603. PubMed · In our library
  35. Gimblet CJ, Ernst JW, Bell B, et al. Effect of glycocalyx-targeted therapy on vascular function in older adults: a randomized controlled trial (n=23, 12 weeks). Journal of Applied Physiology. 2024;136(6):1488–1495. PubMed · In our library
  36. Guse EC, Cotet IG, Mateescu DM, et al. Peripheral microvascular and endothelial dysfunction as predictors of cognitive decline and small vessel disease: a systematic review and meta-analysis. Journal of Clinical Medicine. 2025;14(23):8543. PubMed

About

Who wrote this

Robert Long

Robert Long

Co-Founder, GlycoCalyx Research Institute

Co-founder of Genesis Health Sciences and the GlycoCalyx Research Institute, and a co-author on published trials of glycocalyx-targeted nutrition.

Dr Hans Vink, PhD

Dr Hans Vink, PhD

Scientific review · Co-Founder & Chief Science Officer

Internationally recognised vascular scientist and a pioneer of endothelial glycocalyx research, with 250+ published papers and over 16,000 citations across more than two decades. Dr Vink reviewed this article for scientific accuracy.

GlycoCalyx Research Institute

Genesis Health Sciences

The Institute develops and studies nutrition for the endothelial glycocalyx, and distributes the GlycoCheck™ microvascular assessment in the United States. Browse the research library →

Measure the half nobody measures

Losing weight is the easy number to watch.

Your capillary bed is the one that decides how the next twenty years go — peripheral microvascular dysfunction predicts cognitive decline and small-vessel disease years ahead of it. Test it, feed it, and check it again.

Shop ReVasca® Find a GlycoCheck™ clinic ReCelyx™ micronutrients ReMyolyx™ amino acids Research library

GlycoCheck™ is a Class I medical device used to assess microvascular health. Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration; ReVasca®, ReCelyx™ and ReMyolyx™ are not intended to diagnose, treat, cure or prevent any disease. ReVasca® contains soybeans; ReMyolyx™ contains L-phenylalanine. Individual results vary. This article is educational and is not a substitute for advice from your own healthcare professional. It is not medical advice about GLP-1 receptor agonist therapy; decisions about prescribed medication belong with the clinician who prescribed it. Semaglutide, tirzepatide, liraglutide and dulaglutide are the property of their respective manufacturers; GlycoCalyx Research Institute is not affiliated with, endorsed by or sponsored by any of them.

Back to blog